Many novel agents have been approved for R/R MCL cases, including mTOR inhibitors, immunomodulatory drugs, proteasome inhibitors, and Bruton tyrosine kinase (BTK) inhibitors [16,17,18,19]. This evidence concerns the gene BTK and mantle cell lymphoma.